Results 141 to 150 of about 8,529 (239)

Unveiling Hepatic Protein Alterations in Neonatal and Infant Biliary Atresia

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1584-1596, June 2026.
Pediatric populations differ from adults in drug elimination capacity. While current scaling methods account for enzyme and transporter maturation, they overlook comorbidities, such as biliary atresia (BA), a liver disease appearing within the first 2–8 weeks of life that can progress to cirrhosis.
Zubida M. Al‐Majdoub, Martyn Howard, Brahim Achour, Jill Barber, Naved Alizai, Amin Rostami‐Hodjegan   +5 more
wiley   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

A permeability- and perfusion-based PBPK model for improved prediction of concentration-time profiles. [PDF]

Clin Transl Sci, 2022
Korzekwa K, Radice C, Nagar S.
europepmc   +1 more source

Extracellular Vesicles as Enabling Biomarkers for New Approach Methodologies to Support the US Food and Drug Administration Modernization Act 3.0

Journal of Extracellular Vesicles, Volume 15, Issue 6, June 2026.
ABSTRACT The FDA Modernization Act 3.0 represents a pivotal shift in biomedical research by formally removing the requirement for animal testing and enabling regulatory acceptance of New Approach Methodologies (NAMs). This transition creates an urgent need for robust, human‐relevant biomarkers that can anchor NAM‐generated data within regulatory ...
Andrew Rowland, Carl Kirkpatrick, A David Rodrigues, Uli Frevert, Franziska Haderk, David W Greening, Andrew J McLachlan, Ashley Hopkins, Fabrice Lucien, Rienk Nieuwland   +9 more
wiley   +1 more source

Correction to: A PBPK model to evaluate zebrafish eleutheroembryos' actual exposure: bisphenol A and analogs' (AF, F, and S) case studies. [PDF]

Environ Sci Pollut Res Int, 2023
Billat PA, Brochot C, Brion F, Beaudouin R.   +3 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling of Elexacaftor/Tezacaftor/Ivacaftor in Infants With Cystic Fibrosis

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 6, June 2026.
ABSTRACT Ivacaftor is the only cystic fibrosis transmembrane conductance regulator modulator approved for infants ≥ 1 month. The elexacaftor/tezacaftor/ivacaftor combination, approved for children aged ≥ 2 years, has been shown to significantly slow CF progression.
Ngoc Hoa Truong, Sihem Benaboud, Naïm Bouazza, Eric Deneuville, Anne Mornand, Philippe Reix, Mélanie Ribault, Pierre‐Régis Burgel, Léo Froelicher‐Bournaud, Steeve Rouillon, Mohammed Rohi Sanoufi, Gabrielle Lui, Saïk Urien, Jean‐Marc Tréluyer, Isabelle Sermet‐Gaudelus, Frantz Foissac, Modul‐CF study group, Melissa Baravalle, Mahassen Barboura, Lilia Benhalla, Khadidja Bennour, Katia Bessaci, Antoine Bessou, Thiphaine Bihouée, Anne‐Sophie Bonnel, Nesrine Bouleghem, Stéphanie Bui, Frédérique Chedevergne, Harriet Corvol, Laure Cosson, Laure Couderc, Marie‐Laure Dalphin, Paola De Carli, Eric Deneuville, Pierre Foucaud, Asma Gabsi, Elsa Gachelin, Fatiha Hassani, Véronique Houdouin, Frédéric Huet, Marie Jamin, Kadiatou Kaba, Guillaume Labbé, Jane Languepin, Muriel Laurans, Cathy Léréna, Alexia Letierce, Clotilde Livrozet, Christophe Marguet, Laurent Mély, Rania Messaoudi, Marie Mittaine, Camille Ohlmann, Caroline Périsson, Thomas Perrin, Carole Piccini‐Bailly, Cinthia Rames, Philippe Reix, Natascha Rémus, Anna Ronayette, Djouher Sahki, Manuela Scalbert, Isabelle Sermet, Floriane Socchi, Nathalie Stremler, Aurélie Tatopoulos, Guillaume Thouvenin, Tom Toin, Françoise Troussier, Laurence Weiss, Marie‐Christine Werck‐Galois, Nathalie Wizla   +71 more
wiley   +1 more source

Integration of Machine Learning With PBPK and QSAR Modeling Approaches to Facilitate Drug Discovery and Development

CPT: Pharmacometrics & Systems Pharmacology
This review examines the application of machine learning (ML) in physiologically based pharmacokinetic (PBPK) modeling through improved prediction of input parameters, particularly via quantitative structure–activity relationship (QSAR) models, for ...
Xinyue Chen, Zhoumeng Lin
doaj   +1 more source

Health Risk Assessment in Children Occupationally and Para-Occupationally Exposed to Benzene Using a Reverse-Translation PBPK Model. [PDF]

Int J Environ Res Public Health, 2023
Pech K, Pérez-Herrera N, Vértiz-Hernández ÁA, Lajous M, Farías P.   +4 more
europepmc   +1 more source

Breaking Barriers Between Species: Integrated Multi‐Species PK Models Improve Human PK Predictions

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 6, June 2026.
ABSTRACT The accurate prediction of human pharmacokinetics (PK) is critical for compound selection and determining the human efficacious dose in drug discovery. Besides predicting the key PK parameters clearance (CL) and steady‐state distribution volume (Vss), the prediction of exposure metrics, e.g., maximum and trough concentrations (Cmax, Ctrough ...
Miriam S. R. Happ, Jens M. Borghardt, Charlotte Kloft, Hermann Rapp, Achim Sauer, Anneke Himstedt, Bettina Gerner   +6 more
wiley   +1 more source

A PBPK model to evaluate zebrafish eleutheroembryos' actual exposure: bisphenol A and analogs' (AF, F, and S) case studies. [PDF]

Environ Sci Pollut Res Int, 2023
Billat PA, Brochot C, Brion F, Beaudouin R.   +3 more
europepmc   +1 more source